Evaro Secures $25M: Redefining Digital Healthcare Access
January 31, 2026, 3:38 pm
Evaro, an NHS-licensed digital healthcare innovator, secured $25M Series A funding. The platform lets consumer brands embed regulated health services directly into their apps. This strategy tackles the UK's severe GP waiting lists, making care accessible and convenient. Funds target expansion in women's, men's, and longevity health, plus advanced diagnostics and API platform development. Evaro aims to serve 10 million patients in three years. It pioneers an "embedded health" revolution, offloading pressure from national health systems and streamlining patient access to prescriptions, diagnostics, and aftercare for common conditions.
Evaro has secured $25 million in Series A funding. This significant investment fuels its ambitious growth plans. AlbionVC spearheaded the funding round. Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI also participated. This capital injection follows a €1.4 million Seed round in 2024. Evaro is now positioned for a major expansion in digital health.
Evaro operates as an NHS-licensed digital healthcare platform. It provides critical infrastructure. Its innovative model integrates medical services directly into consumer brands. This allows brands to offer regulated healthcare. They do this without building complex systems from scratch. Evaro’s platform is API-first. This design streamlines integration for any business partner.
The UK faces a severe primary care crisis. General practitioner (GP) appointment wait times are at critical levels. Over 20 million people waited more than a week in 2024. This marks a 60% increase in just seven years. Evaro offers a vital, scalable solution. It significantly expands access to regulated digital healthcare. This strategy directly reduces pressure on the overburdened NHS.
Embedded health works efficiently. Evaro delivers a complete healthcare chain. This includes asynchronous consultations. Remote diagnostics are integral. The platform manages prescribing and dispensing. It also provides essential aftercare services. Integrations are remarkably swift. Partner brands can implement these services within weeks. This model creates valuable new revenue streams. It also deepens customer relationships for those brands.
Evaro has already proven its impact. It serves over two million patients. The company holds stringent licenses. These include Care Quality Commission (CQC), General Pharmaceutical Council (GPhC), and NHS licenses. These credentials ensure safety and regulatory compliance. The platform partners with major consumer brands. The period-tracking app Clue is one example. Sexual wellness retailer Lovehoney is another. They embed prescription services directly into their existing customer experiences. This reaches users where they already engage. Studies affirm the model’s effectiveness. Well-designed asynchronous consultations resolve a high percentage of cases. Up to 66% of primary care cases avoid traditional live appointments.
The new funding targets specific expansion areas. Women's health is a primary focus. Men's health services will also expand significantly. Longevity medicine represents another key growth sector. Evaro plans to advance its clinical capabilities. Cutting-edge diagnostics will see further development. Enhanced aftercare protocols are also in scope. Platform development, especially its robust API infrastructure, remains central to its strategy.
Evaro's funding aligns with broader European HealthTech trends. Investors are increasingly backing regulated, platform-driven models. Digital healthcare solutions are gaining significant traction across the continent. Recent funding rounds highlight this shift. Tucuvi in Spain raised €17 million for voice-AI patient follow-up platforms. GlycanAge in the UK secured €7.4 million for glycan-based ageing diagnostics. Norway's Noteless received €3.5 million for AI documentation to reduce clinician workload. Teton.ai in Copenhagen closed €17 million for predictive hospital intelligence. Poland's Holi added €3 million for its digital obesity treatment platform. These collective investments underscore a clear trend. Scalable, technology-enabled care is reshaping the future of health systems.
The concept of embedded health echoes "embedded finance." Banking transformed through seamless, integrated services. Evaro now drives an "embedded health" revolution. This model unlocks massive latent demand for healthcare. It allows trusted consumer brands to enter the healthcare space. This entry is both safe and fully regulated. Evaro’s infrastructure has been meticulously built over seven years. Deep regulatory credentials form its cornerstone.
Evaro sets ambitious future goals. It plans to serve 10 million patients. This target is set for the next three years. The company seeks to define a new market category: healthcare-as-a-service. This model prioritizes patient convenience above all else. It mirrors modern expectations seen in banking or shopping. Instant, mobile, and on-demand care is the core promise. Evaro builds the essential infrastructure for this modern patient experience.
Evaro stands at the forefront of innovation. It modernizes healthcare access. Its embedded model offers a scalable solution. It directly addresses systemic capacity issues within health systems. The $25 million funding fuels this critical transformation. Evaro is poised to fundamentally reshape how people receive medical care. It brings essential health services directly to millions of individuals.
Evaro has secured $25 million in Series A funding. This significant investment fuels its ambitious growth plans. AlbionVC spearheaded the funding round. Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI also participated. This capital injection follows a €1.4 million Seed round in 2024. Evaro is now positioned for a major expansion in digital health.
Evaro operates as an NHS-licensed digital healthcare platform. It provides critical infrastructure. Its innovative model integrates medical services directly into consumer brands. This allows brands to offer regulated healthcare. They do this without building complex systems from scratch. Evaro’s platform is API-first. This design streamlines integration for any business partner.
The UK faces a severe primary care crisis. General practitioner (GP) appointment wait times are at critical levels. Over 20 million people waited more than a week in 2024. This marks a 60% increase in just seven years. Evaro offers a vital, scalable solution. It significantly expands access to regulated digital healthcare. This strategy directly reduces pressure on the overburdened NHS.
Embedded health works efficiently. Evaro delivers a complete healthcare chain. This includes asynchronous consultations. Remote diagnostics are integral. The platform manages prescribing and dispensing. It also provides essential aftercare services. Integrations are remarkably swift. Partner brands can implement these services within weeks. This model creates valuable new revenue streams. It also deepens customer relationships for those brands.
Evaro has already proven its impact. It serves over two million patients. The company holds stringent licenses. These include Care Quality Commission (CQC), General Pharmaceutical Council (GPhC), and NHS licenses. These credentials ensure safety and regulatory compliance. The platform partners with major consumer brands. The period-tracking app Clue is one example. Sexual wellness retailer Lovehoney is another. They embed prescription services directly into their existing customer experiences. This reaches users where they already engage. Studies affirm the model’s effectiveness. Well-designed asynchronous consultations resolve a high percentage of cases. Up to 66% of primary care cases avoid traditional live appointments.
The new funding targets specific expansion areas. Women's health is a primary focus. Men's health services will also expand significantly. Longevity medicine represents another key growth sector. Evaro plans to advance its clinical capabilities. Cutting-edge diagnostics will see further development. Enhanced aftercare protocols are also in scope. Platform development, especially its robust API infrastructure, remains central to its strategy.
Evaro's funding aligns with broader European HealthTech trends. Investors are increasingly backing regulated, platform-driven models. Digital healthcare solutions are gaining significant traction across the continent. Recent funding rounds highlight this shift. Tucuvi in Spain raised €17 million for voice-AI patient follow-up platforms. GlycanAge in the UK secured €7.4 million for glycan-based ageing diagnostics. Norway's Noteless received €3.5 million for AI documentation to reduce clinician workload. Teton.ai in Copenhagen closed €17 million for predictive hospital intelligence. Poland's Holi added €3 million for its digital obesity treatment platform. These collective investments underscore a clear trend. Scalable, technology-enabled care is reshaping the future of health systems.
The concept of embedded health echoes "embedded finance." Banking transformed through seamless, integrated services. Evaro now drives an "embedded health" revolution. This model unlocks massive latent demand for healthcare. It allows trusted consumer brands to enter the healthcare space. This entry is both safe and fully regulated. Evaro’s infrastructure has been meticulously built over seven years. Deep regulatory credentials form its cornerstone.
Evaro sets ambitious future goals. It plans to serve 10 million patients. This target is set for the next three years. The company seeks to define a new market category: healthcare-as-a-service. This model prioritizes patient convenience above all else. It mirrors modern expectations seen in banking or shopping. Instant, mobile, and on-demand care is the core promise. Evaro builds the essential infrastructure for this modern patient experience.
Evaro stands at the forefront of innovation. It modernizes healthcare access. Its embedded model offers a scalable solution. It directly addresses systemic capacity issues within health systems. The $25 million funding fuels this critical transformation. Evaro is poised to fundamentally reshape how people receive medical care. It brings essential health services directly to millions of individuals.